Compare · PLSE vs RMD
PLSE vs RMD
Side-by-side comparison of Pulse Biosciences Inc (PLSE) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PLSE and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 9.8x PLSE ($3.49B).
- RMD has been more active in the news (9 items in the past 4 weeks vs 7 for PLSE).
- RMD has more recent analyst coverage (25 ratings vs 7 for PLSE).
- Company
- Pulse Biosciences Inc
- ResMed Inc.
- Price
- $49.00-0.45%
- $236.53+1.73%
- Market cap
- $3.49B
- $34.13B
- 1M return
- -
- +16.50%
- 1Y return
- -
- -17.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 7
- 9
- Recent ratings
- 7
- 25
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest PLSE
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Needham initiated coverage on Pulse Biosciences with a new price target
- SEC Form 424B5 filed by Pulse Biosciences Inc
- Pulse Biosciences Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by Pulse Biosciences Inc
- Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
- Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
- Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)